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Abstract: The multifocal nature of prostate cancer (PCa) creates a challenge to patients’ 
outcome prediction and their clinical management. An approach that scrutinizes every cancer 
focus is needed in order to generate a comprehensive evaluation of the disease, and by 
correlating to patients’ clinico-pathological information, specific prognostic biomarker can 
be identified. Our study utilized the Affymetrix SNP 6.0 Genome-wide assay to investigate 
forty-three fresh frozen PCa tissue foci from twenty-three patients. With a long clinical 
follow-up period that ranged from 2.0–9.7 (mean 5.4) years, copy number variation (CNV) 
data was evaluated for association with patients’ PSA status during follow-up. From our 
results, the loss of unique genes on 10q23.31 and 10q23.2–10q23.31 were identified to be 
significantly associated to PSA recurrence (p < 0.05). The implication of PTEN and FAS 
loss (10q23.31) support previous reports due to their critical roles in prostate carcinogenesis. 
Furthermore, we hypothesize that the PAPSS2 gene (10q23.2–10q23.31) may be functionally 
relevant in post-operative PSA recurrence because of its reported role in androgen 
biosynthesis. It is suggestive that the loss of the susceptible region on chromosome 10q, which 
implicates PTEN, FAS and PAPSS2 may serve as genetic predictors of PSA recurrence after 
radical prostatectomy. 
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1. Introduction 
Prostate cancer is the second most commonly diagnosed cancer in males worldwide [1]. It is  
a heterogeneous disease and its complexity presents a challenge that affects prediction of patients’ outcome 
and clinical management. A major feature of prostate cancer heterogeneity is the presence of multiple 
tumor foci within the prostate, which is observed in about 80% of radical prostatectomy specimens [2,3]. 
In recent years, there has been an upsurge of information that has expanded our knowledge of prostate 
cancer genomics. Genomic losses have been observed to occur more frequently when compared to 
genomic gains in prostate cancer [4,5]. From previous studies, androgens and the androgen signaling have 
been acknowledged to be crucial in the growth and progression of the prostate and prostate cancer [6,7]. 
Recognized chromosomal aberrations such as the TMPRSS2-ERG gene fusion, the gain of MYC, and 
the losses of TP53 and PTEN have been shown to be of prognostic value in prostate cancer [7–11].  
The loss of PTEN is perceived to be a chromosomal event with translational impact, as it has been 
associated closely with recurrence of prostate specific antigen (PSA), prostate cancer progression and 
lethality [11,12]. Nevertheless a genomic prognostic marker is yet to be discovered and the major 
challenge in this quest is the observed heterogeneity of prostate cancer. In many cases, the tumors 
possess multiple cell populations with dissimilar genetic alteration profiles [2,13,14]. Presently, PSA 
recurrence following radical prostatectomy is used as a surrogate end-point for monitoring prostate 
cancer relapse [15]. 
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In this study, 43 fresh frozen tumor foci and 10 non-tumor samples from 15 multifocal and 8 unifocal 
prostate cancers were investigated with the Affymetrix SNP 6.0 microarray tool (Affymetrix, Santa 
Clara, CA, USA). Copy number variation data was subsequently correlated to patients’ PSA recurrence 
status. Statistical significant associations are hoped to identify genes in altered chromosomal regions, 
whose biological relevance will reduce the unpredictability of prostate cancer’s progression. 
2. Results and Discussion 
With the Affymetrix Genotyping Console software (version 4.1.2, Affymetrix, Santa Clara, CA, 
USA), each chip experiment was quality controlled (QC) for contrast and intensity. All tumor foci  
(n = 43) show a QC range of 90.3%–98.9% with a mean QC value of 96.5%. For the non-tumor samples 
(nine blood samples and one benign prostate tissue (n = 10)), the QC range is between 96.8%–98.8%, 
with a mean QC value of 98.1%. 
2.1. Chromosomal Copy Number Variation (CNV) Events 
Genome-wide investigation of 43 prostate cancer specimens, nine blood samples and a single benign 
prostate tissue revealed copy number variation data in a total of 627 chromosomal regions in the tumor 
specimens and in 251 chromosomal regions in the benign tissue and blood samples. Comparison of CNV 
data from tumor and non-tumor samples enabled the identification and exclusion of matched CNVs, as 
they are recognized as potential germ-line CNV events. An observed frequency of distinct CNV events 
in 5 tumor foci was utilized as the minimum threshold frequency. The most frequent CNV gains were 
observed on chromosome regions: 22q11.1 (16/43; 37.2%), 16p12.1 (13/43; 30.2%), 15q22.31 (11/43; 
25.6%), 9q21.11 (10/43; 23.3%), 8q21.11 (7/43; 16.3%) and 8q22.3 (7/43; 16.3%). The most frequent 
copy number losses were observed at 8p21.2 (21/43; 48.8%), 8p21.3 (21/43; 48.8%), 8p21.2–8p21.1 
(19/43; 44.2%), 8p21.3–8p21.2 (18/43; 41.9%), 8p23.1–8p22 (15/43; 34.9%), 16q24.1 (14/43; 32.6%), 
18q11.2 (14/43; 32.6%), 8p11.22–8p11.21–8p11.21 (13/43; 30.2%) and 10q23.31 (13/43; 30.2%). The 
genome-wide copy number variation results are summarized in Table 1. The most frequently observed 
chromosomal aberrations were copy number losses situated on the p arm of chromosome 8. 
Table 1. Frequently observed copy number variation regions in investigated tumor foci. The 
gene NKX3-1 is in bold because it is notable within the chromosomal region. 
Copy Number 
Variation Regions 
Number of Individual 
Tumor Foci (n = 43) 
Genes Annotated to the Region 
Gain 
22q11.1 16 (37.2%) OR11H1, POTEH 
16p12.1 13 (30.2%) GSG1L 
15q22.31 11 (25.6%) MEGF11 
9q21.11 10 (23.3%) 
ANKRD20A4, C9orf71, CBWD3, CBWD5, CBWD6, FAM122A, 
FOXD4L3, FOXD4L5, FOXD4L6, PGM5 
8q21.11 7 (16.3%) 
CRISPLD1, GDAP1, HNF4G, JPH1, LY96, MIR2052, PI15, RDH10, 
RPL7, STAU2, UBE2W 
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Table 1. Cont. 
Copy Number 
Variation Regions 
Number of Individual 
Tumor Foci (n = 43) 
Genes Annotated to the Region 
8q22.3 7 (16.3%) 
ATP6V1C1, AZIN1, C8orf56, CTHRC1, DPYS, FZD6, GRHL2, 
KLF10, LRP12, MIR3151, NCALD, ODF1, SLC25A32, TM7SF4 
8q24.13 6 (14%) 
ANXA13, ATAD2, C8orf76, DERL1, FAM83A, FAM91A1, FBXO32, 
FER1L6, KIAA0196, KLHL38, MTSS1, NDUFB9, NSMCE2, 
RNF139, SQLE, TATDN1, TMEM65, TRIB1, TRMT12, WDR67, 
WDYHV1, ZHX1, ZHX1-C8ORF76, ZHX2, ZNF572 
Loss 
8p21.2 21 (48.8%) 
ADAM28, ADAMDEC1, BNIP3L, CDCA2, DPYSL2, KCTD9, NEFL, 
NEFM, NKX2-6, NKX3-1, PNMA2, PPP2R2A, STC1 
8p21.3 21 (48.8%) 
ATP6V1B2, BIN3, BMP1, C8orf58, CHMP7, CSGALNACT1, DOK2, 
EGR3, EPB49, FAM160B2, FGF17, GFRA2, HR, INTS10, 
KIAA1967, LGI3, LPL, LZTS1, MIR320A, NPM2, NUDT18, 
PDLIM2, PEBP4, PHYHIP, PIWIL2, POLR3D, PPP3CC, R3HCC1, 
REEP4, RHOBTB2, SFTPC, SH2D4A, SLC18A1, SLC39A14, 
SORBS3, TNFRSF10A, TNFRSF10B, TNFRSF10C,  
TNFRSF10D, XPO7 
8p21.2–8p21.1 19 (44.2%) CHRNA2, EPHX2, PTK2B, STMN4, TRIM35 
8p21.3–8p21.2 18 (41.9%) ENTPD4 
8p23.1–8p22 15 (34.9%) 
C8orf48, CTSB, DEFB130, DEFB134, DEFB135, DEFB136, DLC1, 
FAM66A, FAM66D, FAM86B1, FAM86B2, FDFT1, KIAA1456, 
LONRF1, MIR3926-1, MIR3926-2, USP17L2, ZNF705D 
16q24.1 14 (32.6%) 
ATP2C2, C16orf74, COTL1, COX4I1, COX4NB, CRISPLD2, 
FAM92B, FOXC2, FOXF1, FOXL1, GINS2, IRF8, KCNG4, 
KIAA0182, KIAA0513, KIAA1609, MIR1910, MTHFSD, USP10, 
WFDC1, ZDHHC7 
18q11.2 14 (32.6%) 
ANKRD29, AQP4, C18orf45, C18orf8, CABYR, CHST9, HRH4, 
IMPACT, KCTD1, LAMA3, MIR320C2, NPC1, OSBPL1A, PSMA8, 
RIOK3, SS18, TAF4B, TTC39C, ZNF521 
8p11.22–8p11.21 13 (30.2%) ADAM2, ADAM18 
10q23.31 13 (30.2%) 
ACTA2, ANKRD22, ATAD1, CH25H, FAS, IFIT1, IFIT1B, IFIT2, 
IFIT3, IFIT5, KIF20B, KLLN, LIPA, LIPF, LIPJ, LIPK, LIPM, LIPN, 
MIR107, PANK1, PTEN, RNLS, SLC16A12, STAMBPL1 
10q23.2–10q23.31 10 (23.3%) PAPSS2 
2.2. Establishing Relationship between Copy Number Variation Regions and PSA Recurrence 
For 20 out 23 patients, PSA recurrence status was obtainable. Nine patients show PSA recurrence, 
while 11 patients show no PSA recurrence during 2.0–9.7 (mean 5.4) years of follow-up. Using the 
Fisher’s exact test to compare patients’ follow-up information and copy number variation data, specific 
locations on the chromosome 10q were identified as they showed correlation to PSA recurrence of 
prostate cancer. The copy number loss of 10q23.2–10q23.31 was identified as it correlated significantly 
to PSA recurrence (p < 0.05). Remarkably, the PAPSS2 gene was identified to be annotated to this 
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region. The loss of the PAPSS2 gene was observed in 6 out of 15 tumor foci from patients with PSA 
recurrence and in one out of 22 tumor foci were obtained from patients without PSA recurrence (Table 2). 
However, adjacent to this interesting region is 10q23.31, which also exhibited a copy number loss.  
The loss of the 10q23.31 region did not correlate statistically with PSA recurrence (Table 2).  
Although on closer scrutiny, some distinct altered genes located on 10q23.31 were identified to correlate 
significantly with PSA recurrence (p < 0.05) (Supplementary Information Table S1). The genes 
identified on 10q23.31 were found to be variably altered in individual tumor foci and they include 
ACTA2, ANKRD22, ATAD1, CH25H, FAS, IFIT1, IFIT1B, IFIT2, IFIT3, IFIT5, KIF20B, KLLN, LIPA, 
LIPF, LIPJ, LIPK, LIPM, LIPN, MIR107, PANK1, PTEN, RNLS, SLC16A12 and STAMBPL1 (Table 1). 
As shown in Figure 1, Table 2 and Table S2, the altered genes: ATAD1, KLLN, PTEN, RNLS, ANKRD22, 
LIPF, LIPK, LIPM, LIPN, ACTA2, FAS and STAMBPL1 were distinctly identified to be significantly 
associated to PSA recurrence (p < 0.05). They were noticeably altered in a significant number of tumor 
foci obtained from patients with PSA recurrence after surgical treatment. Of the genes residing in the 
10q23.31 region, PTEN and FAS are considered to be the major players in prostate tumorigenesis. The 
PTEN and FAS genes were observed to be lost in 6 of 15 tumor foci from patients with PSA recurrence 
and in two out of 22 tumor foci from patients without PSA recurrence patients. In summary, the data 
obtained shows that the chromosomal regions 10q23.2–10q23.31 and 10q23.31 are frequently lost in 
prostate cancer and possibly more than one gene in the regions may be associated to PSA recurrence 
after radical prostatectomy. 
Table 2. Summary of statistical correlation of copy number variation regions and patients 
follow-up data.  
Regions with Copy Number Loss 
Genomic Position (Start–End) a 
Genes Implicated b 
PSA Recurrence 
Yes (n = 9) No (n = 11) 
10q23.2–10q23.31  
chr. 10: 89351602–89572982 
PAPSS2 6/9 (66.7%) * 1/11 (9.1%) 
10q23.31  
chr. 10: 89572982–91817088 
ACTA2, ANKRD22, ATAD1, CH25H, FAS, IFIT1, 
IFIT1B, IFIT2, IFIT3, IFIT5, KIF20B, KLLN, 
LIPA, LIPF, LIPJ, LIPK, LIPM, LIPN, MIR107, 
PANK1, PTEN, RNLS, SLC16A12, STAMBPL1 
7/9 (77.8%) 3/11(27.3%) 
a Genomic position obtained from the Partek summary report with Refseq annotation; b Official gene symbols 
obtained from the Partek summary report with Refseq annotation; * Statistical significance using Fisher’s exact 
test (p < 0.05). 
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Figure 1. Summary illustration of genes with copy number losses located on chromosomes 
10q23.31 and 10q23.2–0q23.31 (PAPSS2). Red shaded boxes indicate tumor foci with losses 
for specified genes. For tumor sample IDs, multifocal prostate cancers are highlighted in 
green and unifocal prostate cancers are not highlighted with color. In addition, the tumor foci 
were sub-categorized into groups based on the patients’ PSA recurrence status. 
2.3. Discussion 
The Affymetrix SNP 6.0 microarray tool kit was utilized to evaluate 15 patients with multifocal and  
8 patients with unifocal prostate cancers. This investigation provided copy number variation data that 
exhibited the most frequent losses on 8p, 10q, 16q and gains on 8q. Chromosomal aberrations in these regions 
have been identified in previous studies and are compatible with our observations [16–18]. The copy number 
losses on chromosome 8p are the most recognized genetic variations in prostate cancer and this 
chromosomal feature is deemed the initiation site of prostate carcinogenesis [19]. The 8p region holds a large 
number of tumor suppressor genes; however it has been challenging to identify the specific “driver” of 
prostate tumorigenesis [20]. The most notable is the NKX3-1 gene, which is located on 8p21.2 (Table 2). It 
is believed that NKX3-1 is crucial in the normal development of the prostate since it has been observed 
to be frequently lost in prostate cancer and PIN (prostatic intraepithelial neoplasia) lesions [21,22]. 
Due to the similarities of our genome-wide copy number variation data to earlier genomic study 
results, the goal of this study was to correlate copy number variation data to patients’ follow-up 
information (PSA recurrence status). In order to identify statistical correlations, all frequently altered 
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chromosomal regions were utilized (Tables 1 and S1). A statistical relationship was recognized between 
the loss of 10q23.2–10q23.31, the loss of unique genes residing on 10q23.31 and PSA recurrence  
(p < 0.05). Although the losses on chromosome 8p, 13q and 16q were observed so frequently (Tables 1 
and S1), they were not significantly linked to post-operative PSA recurrence. From the gene set (Table 2 
and Figure 1), the following genes were identified distinctly to be associated with PSA recurrence: 
PAPSS2, ATAD1, KLLN, PTEN, RNLS, ANKRD22, LIPF, LIPK, LIPM, LIPN, ACTA2, FAS and 
STAMBPL1. The copy number losses of PTEN, FAS and PAPSS2 were distinctly observed in the same 
unique tumor specimens (Figure 1). It is observed in prostate cancer that alterations such as deletions occur 
very often and span large genomic areas, thereby involving several genes. These genes, which are 
implicated in these susceptible areas may individually have prognostic implications. There is the need for 
these genes to be investigated further through functional analysis and comparative gene expression studies. 
However it is important that these genes are discussed and their biological functions briefly highlighted. 
PTEN is the most recognized tumor suppressor gene in the region and is regarded to be a major player 
in prostate carcinogenesis [23]. The loss of PTEN has been strongly associated to PSA recurrence and 
progression of prostate cancer [12]. An astonishing observation was made by Haffner et al. [24], where 
they reported that PTEN is exclusively lost in distinct cancer lesions. They observed the loss of PTEN 
in distinct primary tumors and in seven evaluated metastatic sites. With this unique genetic profile, they 
suggested that the loss of PTEN indicated a monoclonal relationship between defined primary tumors 
and metastasis, and that the loss of PTEN may be a predictor of prostate cancer lethality. From these 
reports and in conjunction with our observation, PTEN is increasingly perceived to be a valuable 
predictive marker for prostate cancer. However, the use of PTEN as a prognostic indicator has been met 
with limitations due to its non-specificity to prostate cancer. It is well-known to be deleted in many 
human cancers [25,26]. 
Within the frequently deleted locus of 10q23.31 and its neighboring region 10q23.2–10q23.31, the 
genes FAS and PAPSS2 were identified to be lost. These genes are selected for discussions because of their 
biological functions in humans and their potential association with PSA recurrence. The aforementioned 
FAS gene belong to the tumor necrosis factor (TNF) family and encodes the FAS (Fatty acid synthase) 
receptor, which is an apoptosis initiator [27]. FAS triggers the apoptotic signaling by binding to the FAS 
ligand, since it is understood that FAS ensures that programmed cell death takes place in tissues. 
Therefore, the eventual loss of FAS, which is observed in several cancers is associated with reduced 
apoptosis, increased cellular proliferation and evasion of tumor cells [28,29]. PTEN and FAS have been 
reported to have an interactive relationship. It is described that PTEN regulates cellular survival and 
progression by inhibiting the phosphatidylinositol-3 kinase/Akt pathway, this it does by recruiting the 
apoptotic FADD (Fas-associated via death domain) mechanisms [30]. 
From this study, the PAPSS2 (3'-phosphoadenosine 5'-phosphosulfate synthase 2) gene was solely 
annotated to the 10q23.2–10q23.31 region and also identified to correlate with PSA recurrence. Here,  
it is necessary to highlight the hypothetical effect of PAPSS2 loss on PSA recurrence. Its influence on 
PSA recurrence may be due to its role in the regulation of dehydroepiandrosterone (DHEA), which is a 
precursor for testosterone (Figure 2). PAPSS2 gene encodes the 3'-phosphoadenosine 5'-phosphosulfate 
synthase 2, which catalyzes the formation of PAPS (3'-phosphoadenosine-5'-phosphosulfate) via a  
2-phase biosynthetic process. PAPS is a sulfate (SO42−) donor that is required in many post-translational 
biological reactions [31] and actively involved in the sulfation conjugation of xenobiotic compounds [32]. 
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The formation of PAPS from PAPSS2 utilizes inorganic sulfates and ATP (adenosine triphosphate) as 
substrates and it involves these phases: (1) reaction of inorganic sulfate and ATP to form APS (adenosine 
5'-phosphosulfate) and (2) the subsequent reaction of APS with ATP to form PAPS [31,33,34].  
Although the alteration of PAPSS2 gene has been clinically associated to Pakistani type of 
spondyloepimetaphyseal dysplasia (SEMD) [34] and colon cancer [35], it has not been shown to be 
strongly associated to prostate cancer. However, PAPSS2 has been reported to be poorly expressed in 
prostate cancer and may have a distinct role in prostate carcinogenesis [36]. Here we hypothesize that 
the copy number loss of PAPSS2 gene may lead to non-functional PAPSS2, which is unable to generate 
PAPS resulting in the accumulation of DHEA [34]. An increased level of DHEA is predicted to increase 
the rate of androgen biosynthesis and a potential increase of PSA levels. PSA is a target product of 
androgen receptor activity [37]. 
It was reported earlier that there may be two or more tumor suppressor genes in the 10q23–26 
chromosomal region [38] due to the frequent loss of PTEN and its neighboring genes in prostate cancer [36]. 
With the implication of PTEN, FAS and PAPSS2 genes on 10q23.2–10q23.31 and 10q23.31, it is 
possible that the loss of these genes is critical in the pathogenesis of prostate cancer. PTEN has been 
studied frequently and is reported to possess important tumor suppressor roles, FAS is reported also to 
have pro-apoptotic functions and PAPSS2 is hypothetically a regulator of androgen biosynthesis.  
Their biological functions indicate that there may be a relationship between the genetic loss of these three 
genes PTEN, FAS, PAPSS2 and the PSA recurrence status of prostate cancer patients. The observed 
simultaneous loss of PTEN, FAS and PAPSS2 genes in prostatic tissues may have the potential of 
predicting PSA recurrence in patients after radical prostatectomy. 
(A) (B) 
Figure 2. Hypothetical influence of PAPSS2 gene in PSA recurrence. The encoded PAPSS2 
protein may have an effect on androgen biosynthesis and PSA recurrence. (A) PAPSS2 regulates 
the formation of PAPS, which subsequently regulates the conversion of excess DHEA to inactive 
DHEAS; (B) The absence of PAPSS2 and PAPS, results in the accumulation of DHEAS, 
formation of active androgens, activation of the androgen receptor. PAPSS2 = 3'-phosphoadenosine 
5'-phosphosulfate synthase 2; PAPS = phosphoadenosine-phosphosulfate; DHEA = 
dehydroepiandrosterone; DHEAS = Dehydroepiandrosterone sulfate; SULT2A1 = DHEA 
sulfotransferase; PSA = prostate specific antigen. Adapted from [34,39]. 
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3. Experimental Section 
3.1. Patients 
Patients with multifocal and unifocal prostate cancer were treated with radical prostatectomy from 
1998 to 2007 at the University Hospital Muenster, Germany and Erasmus Medical Center, Rotterdam, 
The Netherlands. Multifocal prostate cancer specimens were characterized with two or more tumor foci 
embedded in the prostate and the unifocal prostate cancer specimens were identified with a single tumor 
focus. The tumors were characterized by indicated clinical-pathological factors (Table 3). The age of  
the patients ranged from 50–71 years and the average patient age was 60 years at time of surgery.  
The pathological stage ranged from pT2 to pT4 and the Gleason score sum of individual tumor sections 
ranged from 6 to 9. 
Following radical prostatectomy, PSA concentration in blood is expected to be below the lower limit 
of detection of the PSA assay. Since <0.1 ng/mL is the achievable lower limit of detection in modern 
PSA immuno-assays, all patients in this study were classified as having PSA recurrence if they had two 
consecutive PSA concentrations above 0.1 ng/mL, which progressed to higher PSA concentration during 
longer follow-up. Serum PSA measured before surgical treatment ranged from 3.68 to 45.2, with a mean 
of 12.5 ng/mL. Post-surgical serum PSA was measured twice yearly to evaluate PSA recurrence. 
Information on PSA recurrence was obtained from a follow-up period of 2.0–9.7 years, with a mean 
follow-up period of 5.4 years and a median follow-up period of 5.9 years. Nine patients had PSA 
recurrence during follow-up, 11 patients had no PSA recurrence and no PSA recurrence information 
could be obtained from three patients. 
Table 3. Clinical-pathological parameters of prostate cancer patients. 
Clinical Parameter Status n (%) 
Age (years) 
<60 10 (43.5%) 
>60 13 (56.5%) 
Focality 
Multifocal 15 (65%) 
Unifocal 8 (35%) 
Pathological tumor stage (pT) 
pT2 5 (21.7%) 
pT3 17 (73.9%) 
pT4 1 (4.35%) 
Gleason score 
≤7 22 (51.2%) 
>7 21 (48.8%) 
PSA recurrence * 
yes 9 (45%) 
no 11 (55%) 
* Information on patients’ PSA recurrence status is available for only 20 out of 23 patients. 
3.2. Clinical Specimens 
Forty three fresh-frozen prostate cancer specimens and ten non-tumor samples (nine blood samples 
and one histological benign fresh-frozen prostate specimen) were obtained from 15 patients with 
multifocal prostate cancers and eight patients with unifocal prostate cancers. Two separate tumor foci 
were obtained from 15 multifocal prostate cancers (n = 30), while two tumor specimens were excised 
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from different flanks of a large tumor from five unifocal prostate cancer cases (n = 10). In addition, single 
tumor foci were obtained from three unifocal prostate cancer cases (n = 3). The focality of the prostate 
cancer cases was determined from pathological reports, which contain topographical maps of locations of 
adenocarcinoma foci within the prostate gland [40,41]. The preparation and handling of tissue portions 
from the left and right side of the prostate have been previously described in Ibeawuchi et al. [13]. 
3.3. Quality Control and Data Analysis 
Preparation of DNA and subsequent genome-wide analysis have been concisely described in 
Ibeawuchi et al. [13]. Each analyzed chip was quality controlled with the Affymetrix Genotyping 
Console software (version 4.1.2, Affymetrix, Santa Clara, CA, USA) [42]. Afterwards, intensity data as 
CEL files were exported for further analysis into the Partek® Genomic Suite software (version 6.6) 
(Partek Incorporated, St. Louis, MO, USA) [43]. In the Partek Genomic Suite, all experimental CEL 
files were normalized against a Universal Reference (Hapmap 270 control samples). The Affymetrix 6.0 
microarray chip contain more than 906,600 SNP (single nucleotide polymorphism) probes and these 
SNPs were exclusively interrogated for copy number variation (CNV) analysis by the genomic 
segmentation algorithm. To evaluate CNV, the genomic segmentation algorithm was utilized with the 
following parameters: minimum genomic markers/probes of 10, p-value of ≤0.001 and signal to noise 
ratio of 2 ± 0.3 (limits of detecting the normal range in a diploid region: 1.7 to 2.3). The Genomic 
segmentation algorithm [44] conducts its task of copy number analysis in two steps: Firstly, a breakpoint 
was established and secondly, the aberration status of that chromosomal region was ascertained.  
A breakpoint is recognized when a two-sided t-test statistically compares two neighboring regions/ 
segments and there is a significant change in chromosomal abundance (p < 0.001). The aberration status 
of the region is thus established when a one-sided t-test was used to statistically compare the probe 
distributions mean of the chromosomal regions to the expected range of the normal (1.7 to 2.3). 
Annotations of significant regions were conducted with Refseq [45,46] and subsequent data handling was 
conducted with Microsoft® Office Excel 2010 (Microsoft Corporation, Redmond, WA, USA). 
3.4. Statistical Analysis 
PSA recurrence status of patients was denoted with a “yes” or “no” based on serum PSA concentration 
levels during follow-up. Statistical associations of CNV altered regions and patients’ clinical-pathological 
data were evaluated by using Fisher exact test. p-values obtained in all tests were considered significant 
at p < 0.05. Statistical analysis was conducted using the Spotfire© S+ 8.1 statistical software package 
(Tibco© software Inc., Palo Alto, CA, USA). 
4. Conclusions 
We report that our copy number variation data reveals the loss of PTEN, FAS (10q23.31) and PAPSS2 
(10q23.2–10q23.31) and these altered genes were found to be statistically associated to PSA recurrence. 
Although the exact influence of these genes on PSA recurrence is still unknown, they may be promising 
indicators to predict patients’ outcome. In addition, we draw attention to PAPSS2, which holds important 
biological functions that may increase our understanding of the biology of PSA recurrence and prostate 
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cancer relapse. Based on the correlation between the copy number losses of PTEN, FAS, PAPSS2 and 
PSA recurrence and with the current quest for an improved biomarker, it is recommended that the 
molecular function and translational implication of PTEN, FAS, and PAPSS2 loss in prostate cancer are 
further investigated. 
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